Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zhengye Biotechnology Holding (ZYBT) Buildings (2023 - 2025)

Zhengye Biotechnology Holding has reported Buildings over the past 3 years, most recently at $22.1 million for Q4 2025.

  • Quarterly Buildings rose 3.79% to $22.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $22.1 million through Dec 2025, up 3.79% year-over-year, with the annual reading at $22.4 million for FY2025, 6.97% up from the prior year.
  • Buildings was $22.1 million for Q4 2025 at Zhengye Biotechnology Holding, up from $21.3 million in the prior quarter.
  • Over five years, Buildings peaked at $22.1 million in Q4 2025 and troughed at $21.1 million in Q4 2023.
  • The 3-year median for Buildings is $21.3 million (2024), against an average of $21.5 million.
  • Year-over-year, Buildings increased 1.0% in 2024 and then grew 3.79% in 2025.
  • A 3-year view of Buildings shows it stood at $21.1 million in 2023, then rose by 1.0% to $21.3 million in 2024, then grew by 3.79% to $22.1 million in 2025.
  • Per Business Quant, the three most recent readings for ZYBT's Buildings are $22.1 million (Q4 2025), $21.3 million (Q4 2024), and $21.1 million (Q4 2023).